{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:16:23Z","timestamp":1757618183654,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH_E_113287"],"award-info":[{"award-number":["TSGH_E_113287"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Proton pump inhibitors (PPIs) used for gastrointestinal-related disorders are associated with increased insulin resistance, a risk factor for worsening hyperuricemia. However, lansoprazole has shown potential in reducing insulin resistance by increasing the expression of peroxisome proliferator-activated receptor gamma and CCAAT\/enhancer-binding protein alpha mRNA in adipogenesis. This study aims to investigate the effects of lansoprazole compared to other PPIs in reducing the risk of gout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study on patients using lansoprazole from 2000 to 2005, based on the Taiwan National Health Insurance Database, with follow-up until 2013. A comparison cohort on other PPIs was selected through propensity score matching for age, sex, comorbidities, and concomitant medications. Gout risk was analyzed using survival analysis and a Cox proportional hazards model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1816 lansoprazole users, 139 developed gout (7.7%), compared to 968 (13.3%) out of 7264 in the other PPIs group. The average age was 53.33 (\u00b1\u200914.79) in the lansoprazole group and 52.71 (\u00b1\u200914.81) in the other PPIs group. The cumulative incidence of gout was lower in the lansoprazole cohort, with a significantly reduced gout risk (adjusted hazard ratio, 0.64; 95% CI, 0.56\u20130.73). This lower risk remained after stratification by gender and among individuals over 30\u00a0years old.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Among PPI users, lansoprazole is associated with a significantly lower risk of gout. For patients at risk of gout who require PPI therapy, lansoprazole may be considered the treatment of choice.<\/jats:p>\n            <jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>The cumulative incidence of gout is lower in lansoprazole users than in other PPI users<\/jats:italic>\u2022 <jats:italic>Lansoprazole users had a significant lower risk of developing gout compared to other PPI users<\/jats:italic>\u2022 <jats:italic>Lansoprazole may be considered for patients at risk of gout<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07502-z","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:44:41Z","timestamp":1748933081000},"page":"2971-2979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lansoprazole associated with a relatively lower gout risk among PPI users: a nationwide retrospective study"],"prefix":"10.1007","volume":"44","author":[{"given":"Hung-Kai","family":"Shih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Te","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sy-Jou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Chih","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung\u2010Kun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Kuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen\u2010Tung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4169-921X","authenticated-orcid":false,"given":"Ming-Hsun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"9","key":"7502_CR1","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","volume":"79","author":"LGT Shanika","year":"2023","unstructured":"Shanika LGT, Reynolds A, Pattison S, Braund R (2023) Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol 79(9):1159\u20131172. https:\/\/doi.org\/10.1007\/s00228-023-03534-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"7502_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","volume":"153","author":"MF Vaezi","year":"2017","unstructured":"Vaezi MF, Yang YX, Howden CW (2017) Complications of proton pump inhibitor therapy. Gastroenterology 153(1):35\u201348. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.047","journal-title":"Gastroenterology"},{"issue":"1","key":"7502_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/nyas.14428","volume":"1481","author":"IE Perry","year":"2020","unstructured":"Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ (2020) Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci 1481(1):43\u201358. https:\/\/doi.org\/10.1111\/nyas.14428","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"7502_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.62476\/abess105","volume":"9","author":"M Karada\u011f","year":"2024","unstructured":"Karada\u011f M (2024) Use of Prunus armeniaca L. Seed oil and pulp in health and cosmetic products. Adv Biol Earth Sci 9(1):105\u2013110. https:\/\/doi.org\/10.62476\/abess105","journal-title":"Adv Biol Earth Sci"},{"issue":"1","key":"7502_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.62476\/abes9196","volume":"9","author":"K Miryusifova","year":"2024","unstructured":"Miryusifova K (2024) The saffron effects on the dynamics of experimental epilepsy. Adv Biol Earth Sci 9(1):196\u2013202. https:\/\/doi.org\/10.62476\/abes9196","journal-title":"Adv Biol Earth Sci"},{"issue":"2","key":"7502_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.diabres.2008.11.019","volume":"83","author":"L Lima Mde","year":"2009","unstructured":"Lima Mde L, Cruz T, Rodrigues LE, Bomfim O, Melo J, Correia R et al (2009) Serum and intracellular magnesium deficiency in patients with metabolic syndrome\u2013evidences for its relation to insulin resistance. Diabetes Res Clin Pract 83(2):257\u2013262. https:\/\/doi.org\/10.1016\/j.diabres.2008.11.019","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"7502_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.2337\/dc11-1833","volume":"35","author":"N Friedrich","year":"2012","unstructured":"Friedrich N, Thuesen B, Jorgensen T, Juul A, Spielhagen C, Wallaschofksi H et al (2012) The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 35(4):768\u2013773. https:\/\/doi.org\/10.2337\/dc11-1833","journal-title":"Diabetes Care"},{"issue":"4","key":"7502_CR8","doi-asserted-by":"publisher","first-page":"e13846","DOI":"10.1111\/apha.13846","volume":"235","author":"LMM Gommers","year":"2022","unstructured":"Gommers LMM, Hoenderop JGJ, de Baaij JHF (2022) Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf) 235(4):e13846. https:\/\/doi.org\/10.1111\/apha.13846","journal-title":"Acta Physiol (Oxf)"},{"issue":"6","key":"7502_CR9","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1111\/bcp.15182","volume":"88","author":"P Czarniak","year":"2022","unstructured":"Czarniak P, Ahmadizar F, Hughes J, Parsons R, Kavousi M, Ikram M et al (2022) Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol 88(6):2718\u20132726. https:\/\/doi.org\/10.1111\/bcp.15182","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"7502_CR10","doi-asserted-by":"publisher","first-page":"e120124225581","DOI":"10.2174\/0115733998254869231101095222","volume":"20","author":"S Chenchula","year":"2024","unstructured":"Chenchula S, Sharma P, Ghanta MK, Amerneni KC, Rajakarunakaran P, Saggurthi P et al (2024) Association and mechanisms of proton pump inhibitors use with type-2 diabetes mellitus incidence in adults: a systemic review and meta-analysis. Curr Diabetes Rev 20(10):e120124225581. https:\/\/doi.org\/10.2174\/0115733998254869231101095222","journal-title":"Curr Diabetes Rev"},{"issue":"9","key":"7502_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/1756-185X.14834","volume":"26","author":"KJ Zhu","year":"2023","unstructured":"Zhu KJ, Feng W, Ma XN, Liao PL, Lin CS, Huang JY et al (2023) Proton pump inhibitor use associated with an increased risk of gout: a population-based case-control study. Int J Rheum Dis 26(9):1799\u20131806. https:\/\/doi.org\/10.1111\/1756-185X.14834","journal-title":"Int J Rheum Dis"},{"key":"7502_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.biopha.2018.01.052","volume":"99","author":"S Yuan","year":"2018","unstructured":"Yuan S, Zhang ZW, Li ZL (2018) Antacids\u2019 side effect hyperuricaemia could be alleviated by long-term aerobic exercise via accelerating ATP turnover rate. Biomed Pharmacother 99:18\u201324. https:\/\/doi.org\/10.1016\/j.biopha.2018.01.052","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7502_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES, Li C, Curhan G (2007) Prevalence of the metabolic syndrome in patients with gout: the third national health and nutrition examination survey. Arthritis Care Res: Off J Am Coll Rheumatol 57(1):109\u2013115","journal-title":"Arthritis Care Res: Off J Am Coll Rheumatol"},{"issue":"2","key":"7502_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C Li","year":"2013","unstructured":"Li C, Hsieh M-C, Chang S-J (2013) Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 25(2):210\u2013216","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"7502_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00296-015-3242-0","volume":"35","author":"F Perez-Ruiz","year":"2015","unstructured":"Perez-Ruiz F, Aniel-Quiroga MA, Herrero-Beites AM, Chinchilla SP, Erauskin GG, Merriman T (2015) Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol Int 35(9):1519\u20131524","journal-title":"Rheumatol Int"},{"key":"7502_CR16","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.molmet.2021.101411","volume":"55","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Nagoshi T, Takahashi H, Oi Y, Yoshii A, Kimura H et al (2022) URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice. Mol Metab 55:101411. https:\/\/doi.org\/10.1016\/j.molmet.2021.101411","journal-title":"Mol Metab"},{"key":"7502_CR17","doi-asserted-by":"publisher","first-page":"116897","DOI":"10.1016\/j.lfs.2019.116897","volume":"239","author":"A Benchamana","year":"2019","unstructured":"Benchamana A, Mori H, MacDougald OA, Soodvilai S (2019) Regulation of adipocyte differentiation and metabolism by lansoprazole. Life Sci 239:116897. https:\/\/doi.org\/10.1016\/j.lfs.2019.116897","journal-title":"Life Sci"},{"key":"7502_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1096\/fasebj.2018.32.1supplement.829.11","volume":"32","author":"A Benchamana","year":"2018","unstructured":"Benchamana A, Soodvilai S (2018) Lansoprazole inhibits adipocyte differentiation via LXR-independent mechanism. FASEB J 32:829\u2013911. https:\/\/doi.org\/10.1096\/fasebj.2018.32.1supplement.829.11","journal-title":"FASEB J"},{"issue":"18","key":"7502_CR19","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"C-Y Wu","year":"2012","unstructured":"Wu C-Y, Chen Y-J, Ho HJ, Hsu Y-C, Kuo KN, Wu M-S et al (2012) Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection. JAMA 308(18):1906\u20131913","journal-title":"JAMA"},{"issue":"1","key":"7502_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/pds.1324","volume":"16","author":"CS Gau","year":"2007","unstructured":"Gau CS, Chang IS, Lin Wu FL, Yu HT, Huang YW, Chi CL et al (2007) Usage of the claim database of National Health Insurance Programme for analysis of cisapride-erythromycin co-medication in Taiwan. Pharmacoepidemiol Drug Saf 16(1):86\u201395","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"7502_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"CL Cheng","year":"2011","unstructured":"Cheng CL, Kao YHY, Lin SJ, Lee CH, Lai ML (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20(3):236\u2013242","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7502_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH et al (2019) Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol 11:349\u2013358","journal-title":"Clin Epidemiol"},{"issue":"10","key":"7502_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00011-009-0031-9","volume":"58","author":"Z Miao","year":"2009","unstructured":"Miao Z, Yan S, Wang J, Wang B, Li Y, Xing X et al (2009) Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. Inflamm Res 58(10):659\u2013668. https:\/\/doi.org\/10.1007\/s00011-009-0031-9","journal-title":"Inflamm Res"},{"issue":"3 Pt 2","key":"7502_CR24","doi-asserted-by":"publisher","first-page":"F363","DOI":"10.1152\/ajprenal.1995.268.3.F363","volume":"268","author":"JM Callaghan","year":"1995","unstructured":"Callaghan JM, Tan SS, Khan MA, Curran KA, Campbell WG, Smolka AJ et al (1995) Renal expression of the gene encoding the gastric H(+)-K(+)-ATPase beta-subunit. Am J Physiol 268(3 Pt 2):F363\u2013F374. https:\/\/doi.org\/10.1152\/ajprenal.1995.268.3.F363","journal-title":"Am J Physiol"},{"issue":"4","key":"7502_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/phar.2235","volume":"39","author":"E Hart","year":"2019","unstructured":"Hart E, Dunn TE, Feuerstein S, Jacobs DM (2019) Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy 39(4):443\u2013453. https:\/\/doi.org\/10.1002\/phar.2235","journal-title":"Pharmacotherapy"},{"issue":"558","key":"7502_CR26","doi-asserted-by":"publisher","first-page":"eaaz8664","DOI":"10.1126\/scitranslmed.aaz8664","volume":"12","author":"CH Wang","year":"2020","unstructured":"Wang CH, Lundh M, Fu A, Kriszt R, Huang TL, Lynes MD et al (2020) CRISPR-engineered human brown-like adipocytes prevent diet-induced obesity and ameliorate metabolic syndrome in mice. Sci Transl Med. 12(558):eaaz8664. https:\/\/doi.org\/10.1126\/scitranslmed.aaz8664","journal-title":"Sci Transl Med."},{"issue":"11","key":"7502_CR27","doi-asserted-by":"publisher","first-page":"e139160","DOI":"10.1172\/jci.insight.139160","volume":"6","author":"C Cero","year":"2021","unstructured":"Cero C, Lea HJ, Zhu KY, Shamsi F, Tseng YH, Cypess AM (2021) beta3-Adrenergic receptors regulate human brown\/beige adipocyte lipolysis and thermogenesis. JCI Insight. 6(11):e139160. https:\/\/doi.org\/10.1172\/jci.insight.139160","journal-title":"JCI Insight."},{"issue":"4","key":"7502_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tem.2015.01.006","volume":"26","author":"B Gustafson","year":"2015","unstructured":"Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A, Smith U (2015) Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab 26(4):193\u2013200. https:\/\/doi.org\/10.1016\/j.tem.2015.01.006","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"7502_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13098-023-01051-8","volume":"15","author":"MH Lin","year":"2023","unstructured":"Lin MH, Wu WT, Chen YC, Lin TK, Chou YC, Sun CA (2023) Association between clinical use of lansoprazole and the risk of type 2 diabetes mellitus: a pharmacoepidemiological cohort study. Diabetol Metab Syndr 15(1):96. https:\/\/doi.org\/10.1186\/s13098-023-01051-8","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"7502_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/rheumatology\/kex363","volume":"57","author":"SW Niu","year":"2018","unstructured":"Niu SW, Chang KT, Lin HYH, Kuo IC, Chang YH, Chen YH et al (2018) Decreased incidence of gout in diabetic patients using pioglitazone. Rheumatology 57(1):92\u201399. https:\/\/doi.org\/10.1093\/rheumatology\/kex363","journal-title":"Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07502-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:00:24Z","timestamp":1757178024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07502-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7502"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07502-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB No.: A202405037). As the data used were de-identified and released for research purposes, informed consent from the participants was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}